


# CASE STUDIES IN IMMUNOLOGY

A CLINICAL COMPANION

7<sup>TH</sup> EDITION



**RAIF GEHA • LUIGI NOTARANGELO**

# **CASE STUDIES IN IMMUNOLOGY**

A C L I N I C A L C O M P A N I O N

**7<sup>TH</sup> EDITION**

This page intentionally left blank  
to match pagination of print book

# **CASE STUDIES IN IMMUNOLOGY**

A C L I N I C A L C O M P A N I O N

**7<sup>TH</sup> EDITION**

**Raif Geha • Luigi Notarangelo**

Harvard Medical School

 **Garland Science**  
Taylor & Francis Group  
NEW YORK AND LONDON

Vice President: Denise Schanck  
Editor: Christopher Simpson  
Senior Editorial Assistant: Katie Laurentiev  
Production Editor: Natasha Wolfe  
Typesetter: Emma Jeffcock/Georgina Lucas  
Text Editor: Michael Zierler  
Copy Editor: Teresa Wilson  
Proofreader: Susan Wood  
Illustrator: Matthew McClements, Blink Studio, Ltd.  
Indexer: Medical Indexing Ltd.

© 2016 by Garland Science, Taylor & Francis Group, LLC

This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means – graphic, electronic, or mechanical, including photocopying, recording, taping, or information storage and retrieval systems – without permission of the copyright holder.

ISBN 978-0-8153-4512-1

**Library of Congress Cataloging-in-Publication Data**

Names: Geha, Raif S., author. | Notarangelo, Luigi, author.  
Title: Case studies in immunology : a clinical companion / Raif Geha, Luigi Notarangelo.  
Description: 7th edition. | New York, NY : Garland Science, Taylor & Francis Group, LLC, [2016] | Includes index.  
Identifiers: LCCN 2015046364 | ISBN 9780815345121  
Subjects: | MESH: Immune System Diseases | Immunity--genetics | Case Reports  
Classification: LCC RC582 | NLM WD 300 | DDC 616.07/9--dc23  
LC record available at <http://lcn.loc.gov/2015046364>

Published by Garland Science, Taylor & Francis Group, LLC, an informa business,  
711 Third Avenue, New York, NY, 10017, USA, and 3 Park Square, Milton Park, Abingdon, OX14 4RN, UK.

Printed in the United States of America

15 14 13 12 11 10 9 8 7 6 5 4 3 2 1

 **Garland Science**  
Taylor & Francis Group  
NEW YORK AND LONDON

Visit our website at <http://www.garlandscience.com>

# Preface

The science of immunology started as a case study. On May 15, 1796 Edward Jenner inoculated a neighbor's son, James Phipps, with vaccinia (cowpox) virus. Six weeks later, on July 1, 1796, Jenner challenged the boy with live smallpox and found that he was protected against this infection. During the past 220 years, the basic science of immunology has shed light on the pathogenesis of immune-mediated diseases. Conversely, the investigation of diseases of the immune system, particularly of genetically inherited primary immunodeficiency diseases, has provided valuable insights into the functioning of the normal immune system. In recent years, characterization of the molecular basis of inborn errors of immunity has been tremendously accelerated by technological advances in human genomics, in particular whole exome sequencing. As a result of this process, more than 300 primary immunodeficiencies are listed in the most recent classification of the International Union of Immunological Societies. At the same time, it has become increasingly evident that different mutations in the same gene may lead to very distinct clinical and immunological phenotypes.

The study of immunology provides a rare opportunity in medicine to relate the findings of basic scientific investigations to clinical problems. The case histories in this book are chosen for three purposes: to illustrate in a clinical context essential points about the mechanisms of immunity; to describe and explain some of the immunological problems often seen in the clinic; and, when possible, to show how the fine characterization of the pathophysiology of genetically-determined human immune disorders may lead to targeted interventions, an approach known as "precision medicine." For this seventh edition, we have added six new cases that are representative of key aspects of immune system development and function, as revealed by specific forms of primary immunodeficiencies. These cases include dedicator of cytokinesis 8 (DOCK8) deficiency, activated PI-3-kinase delta syndrome, increased susceptibility to *Candida* infections, LRBA deficiency, T cell signaling defects, and channelopathies. New concepts, such as metabolic control of T cell activation and T cell fate, mechanisms of regulatory T cell function, and the role of innate sensors and of T<sub>H</sub>17 cell responses in controlling fungal infections, are discussed in these new cases. We have also revised several cases to add newly acquired information about these diseases and novel developments in immunological therapeutic intervention. The cases illustrate fundamental mechanisms of immunity, as shown by genetic disorders of the immune system, immune-complex diseases, immune-mediated hypersensitivity reactions, and autoimmune and alloimmune diseases. They describe real events from case histories, largely, but not solely, drawn from the records of the Boston Children's Hospital and the Brigham and Women's Hospital in Boston, Massachusetts. Names, places, and times have been altered to obscure the identities of the patients; other details are faithfully reproduced. The cases are intended to help medical students and pre-medical students learn about basic immunological mechanisms and understand their importance, and particularly to serve as a review aid, but we believe they will be useful and interesting to any student of immunology.

Each case is presented in the same format. The case history itself is preceded by an introduction presenting basic scientific facts needed to understand the case. The case history is followed by a brief summary of the disease under study and discussion of the clinical findings. Finally, several questions and discussion points highlight the lessons learned. These questions are not intended as a quiz but rather to shed further light on the case.

We are grateful to Dr. George Tsokos of the Beth Israel Deaconess Medical Center for the case on systemic lupus erythematosus, to Dr. Harland Winter of the Massachusetts General Hospital for the case on Crohn's disease, and to Dr. Peter Nigrovic of the Brigham and Women's Hospital for the cases on systemic juvenile idiopathic arthritis and rheumatoid arthritis. We also thank our colleagues at Boston Children's Hospital, namely Dr. Sandra Burchett for the case on acquired immune deficiency syndrome, and Dr. Mary Beth Son for the case on celiac disease. We are grateful to Drs. Lisa Bartnikas, Francisco Bonilla, Talal Chatila, Janet Chou, Ari Fried, Lauren Henderson, Erin Janssen, Andrew Macginnitie, and Douglas McDonald in the Division of Immunology at Boston Children's Hospital for their contribution for the cases on hyper-IgE syndrome, allergic asthma, contact sensitivity to poison ivy, leukocyte adhesion deficiency, IPEX syndrome, ataxia telangiectasia, toxic shock syndrome, channelopathies, X-linked agammaglobulinemia, activation-induced cytidine deaminase, X-linked lymphoproliferative syndrome, systemic juvenile idiopathic arthritis, systemic lupus erythematosus, hereditary angioedema, X-linked hypohydrotic ectodermal dysplasia and immunodeficiency, and IRAK4 deficiency. We are grateful to Dr. Jolan Walter of the Massachusetts General Hospital for the case of hemophagocytic lymphohistiocytosis, to Dr. Itai Pessach of the Chaim Sheba Medical Center for the case of severe congenital neutropenia; Dr. Anna Virginia Gulino of the Assisi Hospital for the case on WHIM syndrome; and Dr. Andrew Shulman of the Children's Hospital of Orange County for the cases on Crohn's disease and multiple sclerosis. We are also greatly indebted to our colleagues Drs. David Dawson, Susan Berman, Lawrence Shulman and David Hafler of the Brigham and Women's Hospital, to Dr. Razzaque Ahmed of the Harvard School of Dental Medicine, to Drs. Ernesto Gonzalez and Scott Snapper of the Massachusetts General Hospital, to Drs. Peter Newburger and Jamie Ferrara of the Departments of Pediatrics of the University of Massachusetts and the University of Michigan, to Dr. Robertson Parkman of the Los Angeles Children's Hospital, to Dr. Fabio Facchetti, Dr. Lucia Notarangelo and Dr. Antonio Regazzoli of the Spedali Civili of Brescia, Italy, to Henri de la Salle of the Centre régional de Transfusion Sanguine in Strasbourg, France, and to Professor Michael Levin of St. Mary's Hospital, London, for supplying case materials. Our colleagues and trainees in the Immunology Division of the Children's Hospital have provided invaluable service by extracting summaries of long and complicated case histories; we are particularly indebted to Drs. Yousef Badran, Catherine Biggs, Pui Lee, and Craig Platt for constructing several case histories. In the course of developing these cases, we have been indebted for expert and pedagogic advice to Alexander Abdelnoor, Fred Alt, Mark Anderson, John Atkinson, Hugh Auchincloss, Stephen Baird, Zuhair K. Ballas, Adam Benham, Leslie Berg, Corrado Betterle, Kurt Bloch, Jean-Laurent Casanova, Talal Chatila, John J. Cohen, Michael I. Colston, Anthony DeFranco, Peter Densen, Susan R. DiGiovanni, Jeannine M. Durdik, Anthony Farone, Ten Feizi, Alain Fischer, Joel Gaikwad, Christopher Goodnow, Mansour Haeryfar, Edward Kaplan, George Miller, Peter Parham, Jaakko Perheentupa, Jennifer Puck, Westley Reeves, Patrick Revy, Perry M. Scanlan, Peter Schur, Anthony Segal, Lisa Steiner, Stuart Tangye, Andrew Taylor-Robinson, Cox Terhorst, Emil Unanue, André Veillette, Jan Vilcek, Mark Walport, Fenella Woznarowska, and John Zabriskie.

We would also like to acknowledge the Garland Science team for their work on the Seventh Edition.

## A note to the reader

The main topics addressed in each case correspond as much as possible to topics that are presented in the Ninth Edition of *Janeway's Immunobiology* by Kenneth Murphy and Casey Weaver. To indicate which sections of *Immunobiology* contain material relevant to each case, we have listed on the first page of each case the topics covered in it. The color code follows the code used for the five main sections of *Immunobiology*: orange for the introductory chapter and innate immunity, blue

for the sections on recognition of antigen, red for the development of lymphocytes, green for the adaptive immune response, purple for the response to infection and clinical topics, and cyan for methods.

## Instructor Resources Website

The images from *Case Studies in Immunology*, Seventh Edition, are available on the Instructor Site in two convenient formats: PowerPoint® and JPEG. They have been optimized for display on a computer. The resources may be browsed by individual cases and there is a search engine. Figures are searchable by figure number, figure name, or by keywords used in the figure legend from the book.

Accessible from [www.garlandscience.com](http://www.garlandscience.com), the Instructor's Resource Site requires registration and access is available only to qualified instructors. To access the Instructor Resource site, please contact your local sales representative or email [science@garland.com](mailto:science@garland.com).

## Contributors

Yousef R. Badran, MD, Fellow, Division of Immunology, Children's Hospital Boston; Research Fellow Pediatrics, Harvard Medical School

Lisa Bartnikas, MD, Attending Physician Instructor in Pediatrics, Division of Allergy & Immunology, Children's Hospital Boston, Harvard Medical School

Catherine Biggs, MD, Fellow, Division of Immunology, Children's Hospital Boston; Research Fellow Pediatrics, Harvard Medical School

Francisco Bonilla, MD, PhD, Program Director, Clinical Immunology, Division of Allergy & Immunology, Children's Hospital Boston; Assistant Professor of Pediatrics, Harvard Medical School

Arturo Borzutzky, MD, Assistant Professor of Allergy, Immunology and Pediatric Rheumatology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile

Sandra Burchett, MD, Clinical Director, Division of Infectious Diseases; Director, Children's Hospital AIDS Program (CHAPS); Director, Immunocompromised Host Service, Children's Hospital Boston; Associate Professor of Pediatrics, Harvard Medical School

Talal Chatila, MD, Director, Food Allergy Program, Children's Hospital Boston; David and Denise Bunning Professor of Pediatrics, Harvard Medical School

Janet Chou, MD, Instructor in Pediatrics, Children's Hospital Boston and Harvard Medical School

Ari Fried, MD, Assistant in Medicine; Instructor of Pediatrics, Children's Hospital Boston, Harvard Medical School

Anna Virginia Gulino, MD, Attending Physician, Department of Pediatrics, Assisi Hospital, Assisi, Italy

Lauren Henderson, MD, MMSc, Clinical Fellow in Pediatrics, Division of Allergy & Immunology, Children's Hospital Boston, Harvard Medical School

Erin Janssen, MD, PhD, Division of Immunology, Children's Hospital Boston; Instructor in Pediatrics, Harvard Medical School

Pui Y. Lee, MD, PhD, Clinical Fellow, Division of Immunology, Children's Hospital Boston, Harvard Medical School

Andrew Macginnitie, MD, Associate Clinical Director, Division of Immunology, Children's Hospital Boston; Assistant Professor of Pediatrics, Harvard Medical School

Douglas McDonald, MD, PhD, Assistant in Medicine, Children's Hospital Boston; Instructor, Harvard Medical School



Peter Nigrovic, MD, PhD, Assistant in Medicine; Director, Center for Adults with Pediatric Rheumatic Illness (CAPRI), Brigham & Women's Hospital; Assistant Professor, Children's Hospital Boston, Harvard Medical School

Itai Pessach, MD, Attending Physician, Chaim Sheba Medical Center, Tel Hashomer, Israel

Craig Platt, MD, PhD, Clinical Fellow in Pediatrics, Children's Hospital Boston, Harvard Medical School

Andrew Shulman, MD, PhD, Staff Member, Pediatric Rheumatology, Children's Hospital of Orange County, California

MaryBeth Son, MD, Assistant in Medicine, Children's Hospital Boston; Instructor, Harvard Medical School

George Tsokos, MD, Chief, Rheumatology Division, Beth Israel Deaconess Medical Center; Professor of Medicine, Harvard Medical School

Jolan Walter, MD, PhD, Director, Pediatric Immunodeficiency Program, Massachusetts General Hospital for Children; Assistant Professor in Pediatrics, Harvard Medical School

Harland Winter, MD, Director, Pediatric Inflammatory Bowel Disease Center, Massachusetts General Hospital; Associate Professor in Pediatrics, Harvard Medical School

# Contents

<b>Case 1</b>	X-linked Agammaglobulinemia	1
<b>Case 2</b>	CD40 Ligand Deficiency	9
<b>Case 3</b>	Activation-Induced Cytidine Deaminase Deficiency	15
<b>Case 4</b>	Common Variable Immunodeficiency	21
<b>Case 5</b>	X-linked Severe Combined Immunodeficiency	27
<b>Case 6</b>	Adenosine Deaminase Deficiency	35
<b>Case 7</b>	Omenn Syndrome	39
<b>Case 8</b>	MHC Class II Deficiency	45
<b>Case 9</b>	DiGeorge Syndrome	51
<b>Case 10</b>	Acquired Immune Deficiency Syndrome (AIDS)	57
<b>Case 11</b>	Graft-Versus-Host Disease	63
<b>Case 12</b>	MHC Class I Deficiency	67
<b>Case 13</b>	X-linked Lymphoproliferative Syndrome	73
<b>Case 14</b>	Hemophagocytic Lymphohistiocytosis	81
<b>Case 15</b>	Chediak–Higashi Syndrome	87
<b>Case 16</b>	Wiskott–Aldrich Syndrome	93
<b>Case 17</b>	Autoimmune Polyendocrinopathy–Candidiasis– Ectodermal Dystrophy (APECED)	101
<b>Case 18</b>	Immune Dysregulation, Polyendocrinopathy, Enteropathy X-linked Disease	105
<b>Case 19</b>	Autoimmune Lymphoproliferative Syndrome (ALPS)	111
<b>Case 20</b>	Hyper IgE Syndrome	117
<b>Case 21</b>	Ataxia Telangiectasia	123
<b>Case 22</b>	Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome (WHIM Syndrome)	129
<b>Case 23</b>	X-linked Hypohidrotic Ectodermal Dysplasia and Immunodeficiency	135
<b>Case 24</b>	Interferon- $\gamma$ Receptor Deficiency	141
<b>Case 25</b>	Severe Congenital Neutropenia	145
<b>Case 26</b>	Chronic Granulomatous Disease	151
<b>Case 27</b>	Leukocyte Adhesion Deficiency	157
<b>Case 28</b>	Recurrent Herpes Simplex Encephalitis	163
<b>Case 29</b>	Interleukin 1 Receptor-Associated Kinase 4 Deficiency	167
<b>Case 30</b>	Congenital Asplenia	173
<b>Case 31</b>	Hereditary Angioedema	179

<b>Case 32</b>	Deficiency of the C8 Complement Component	185
<b>Case 33</b>	Hereditary Periodic Fever Syndromes	189
<b>Case 34</b>	Systemic Juvenile Idiopathic Arthritis	195
<b>Case 35</b>	Rheumatoid Arthritis	199
<b>Case 36</b>	Systemic Lupus Erythematosus	205
<b>Case 37</b>	Crohn's Disease	209
<b>Case 38</b>	Multiple Sclerosis	215
<b>Case 39</b>	Autoimmune Hemolytic Anemia	221
<b>Case 40</b>	Myasthenia Gravis	227
<b>Case 41</b>	Pemphigus Vulgaris	231
<b>Case 42</b>	Celiac Disease	235
<b>Case 43</b>	Acute Infectious Mononucleosis	241
<b>Case 44</b>	Hemolytic Disease of the Newborn	247
<b>Case 45</b>	Toxic Shock Syndrome	251
<b>Case 46</b>	Lepromatous Leprosy	257
<b>Case 47</b>	Allergic Asthma	263
<b>Case 48</b>	Drug-induced Serum Sickness	271
<b>Case 49</b>	Contact Sensitivity to Poison Ivy	277
<b>Case 50</b>	Deficiency of Cytokines 8	283
<b>Case 51</b>	Activated P13KD Syndrome (APDS)	289
<b>Case 52</b>	Increased Susceptibility to <i>Candida</i> Infections	293
<b>Case 53</b>	LPS-Responsive Beige-Like Anchor (LRBA) Deficiency	297
<b>Case 54</b>	T Cell Signaling Defects	303
<b>Case 55</b>	Channelopathies	307
<b>Answers</b>		313
<b>Figure Acknowledgments</b>		357
<b>Index</b>		359

# CASE 1

## X-LINKED AGAMMAGLOBULINEMIA

### An absence of B lymphocytes.

One of the most important functions of the adaptive immune system is the production of antibodies. It is estimated that a human being can make more than one million different specific antibodies. This remarkable feat is accomplished through a complex genetic program carried out by B lymphocytes and their precursors in the bone marrow (Fig. 1.1). Every day about 2.5 billion ( $2.5 \times 10^9$ ) early B-cell precursors (pro-B cells) take the first step in this genetic program and enter the body's pool of pre-B cells. From this pool of rapidly dividing pre-B cells, 30 billion daily mature into B cells, which leave the bone marrow as circulating B lymphocytes, while 55 billion fail to mature successfully and undergo programmed cell death. This process continues throughout life, although the numbers gradually decline with age.

Mature circulating B cells proliferate on encounter with antigen and differentiate into plasma cells, which secrete antibody. Antibodies, which are made by the plasma cell progeny of B cells, protect by binding to and neutralizing toxins and viruses, by preventing the adhesion of microbes to cell surfaces, and, after binding to microbial surfaces, by fixing complement and thereby enhancing phagocytosis and lysis of pathogens (Fig. 1.2).

#### TOPICS BEARING ON THIS CASE:

Humoral versus cell-mediated immunity


Effector functions of antibodies

Effector mechanisms of humoral immunity

Actions of complement and complement receptors

B-cell maturation

Methods for measuring T-cell function



**Fig. 1.1** The development of B cells proceeds through several stages marked by the rearrangement of the immunoglobulin genes. The bone marrow stem cell that gives rise to the B-lymphocyte lineage has not yet begun to rearrange its immunoglobulin genes; they are in germline configuration. The first rearrangements of D gene segments to JH gene segments occur in the early pro-B cells, generating late pro-B cells. In the late pro-B cells, a VH gene segment becomes joined to the rearranged DJH, producing a pre-B cell that is expressing both

low levels of surface and high levels of cytoplasmic  $\mu$  heavy chain. Finally, the light-chain genes are rearranged and the cell, now an immature B cell, expresses both light chains (L chains) and  $\mu$  heavy chains (H chains) as surface IgM molecules. Cells that fail to generate a functional surface immunoglobulin, or those with a rearranged receptor that binds a self-antigen, die by programmed cell death. The rest leave the bone marrow and enter the bloodstream.

This case concerns a young man who has an inherited inability to make antibodies. His family history reveals that he has inherited this defect in antibody synthesis as an X-linked recessive abnormality. This poses an interesting puzzle because the genes encoding the structure of the immunoglobulin polypeptide chains are encoded on autosomal chromosomes and not on the X chromosome. Further inquiry reveals that he has no B cells, so that some gene on the X chromosome is critical for the normal maturation of B lymphocytes.

### The case of Bill Grignard: a medical student with scarcely any antibodies.

Bill Grignard was well for the first 10 months of his life. In the next year he had pneumonia once and several episodes of otitis media (inflammation of the middle ear), and on one occasion developed erysipelas (streptococcal infection of the skin) on his right cheek. These infections were all treated successfully with antibiotics, but it seemed to his mother that he was constantly on antibiotics.


His mother had two brothers who had died, 30 years prior to Bill's birth, from pneumonia in their second year of life, before antibiotics were available. She also had two sisters who were well; one had a healthy son and daughter and the other a healthy daughter.

Bill was a bright and active child who gained weight, grew, and developed normally, but he continued to have repeated infections of the ears and sinuses and twice again had pneumonia. At 2 years 3 months his local pediatrician tested his serum immunoglobulins. He found 80 mg dl<sup>-1</sup> IgG (normal 600–1500 mg dl<sup>-1</sup>), no IgA (normal 50–125 mg dl<sup>-1</sup>), and only 10 mg dl<sup>-1</sup> IgM (normal 75–150 mg dl<sup>-1</sup>).

Bill was started on monthly intramuscular injections of gamma globulin; his serum IgG level was maintained at 200 mg dl<sup>-1</sup>. He started school at age 5 years and

*Two-year-old boy, two maternal uncles died in infancy from infection.*

*Immunoglobulins very low. No tonsils.*



**Fig. 1.2 Antibodies can participate in host defense in three main ways.**

The left-hand column shows antibodies binding to and neutralizing a bacterial toxin, preventing it from interacting with host cells and from causing pathology. Unbound toxin can react with receptors on the host cell, whereas the toxin:antibody complex cannot. Antibodies also neutralize complete virus particles and bacterial cells by binding to them and inactivating them. The antigen:antibody complex is eventually scavenged and degraded by macrophages. Antibodies coating an antigen render it recognizable as foreign by phagocytes (macrophages and polymorphonuclear leukocytes), which then ingest and destroy it; this is called opsonization. The central column shows the opsonization and phagocytosis of a bacterial cell. The right-hand column shows the activation of the complement system by antibodies coating a bacterial cell. Bound antibodies form a receptor for the first protein of the complement system, which eventually forms a protein complex on the surface of the bacterium that favors its uptake and destruction by phagocytes and can, in some cases, directly kill the bacterium. Thus, antibodies target pathogens and their products for disposal by phagocytes.

performed very well despite prolonged absences because of recurrent pneumonia and other infections.

At 9 years of age he was referred to the Children's Hospital because of atelectasis (collapse of part of a lung) and a chronic cough. On physical examination he was found to be a well-developed, alert boy. He weighed 33.5 kg and was 146 cm tall (height and weight normal for his age). The doctor noted that he had no visible tonsils (he had never had a tonsillectomy). With a stethoscope the doctor also heard rales (moist crackles) at both lung bases.

Further family history revealed that Bill had one younger sibling, John, a 7-year-old brother, who also had contracted pneumonia on three occasions. John had a serum IgG level of 150 mg dl<sup>-1</sup>.



Laboratory studies at the time of Bill's visit to the Children's Hospital gave a white blood cell count of 5100  $\mu\text{l}^{-1}$  (normal), of which 45% were neutrophils (normal), 43% were lymphocytes (normal), 10% were monocytes (elevated), and 2% were eosinophils (normal).

Flow cytometry (Fig. 1.3) showed that 85% of the lymphocytes bound an antibody to CD3, a T-cell marker (normal); 55% were helper T cells reacting with an anti-CD4 antibody; and 29% were cytotoxic T cells reacting with an anti-CD8 antibody

*Complete absence of  
B cells.*

**Fig. 1.3** The FACS™ allows individual cells to be identified by their cell-surface antigens and to be sorted.

Cells to be analyzed by flow cytometry are first labeled with fluorescent dyes (top panel). Direct labeling uses dye-coupled antibodies specific for cell-surface antigens (as shown here), whereas indirect labeling uses a dye-coupled immunoglobulin to detect unlabeled cell-bound antibody. The cells are forced through a nozzle in a single-cell stream that passes through a laser beam (second panel). Photo-multiplier tubes (PMTs) detect the scattering of light, which is a sign of cell size and granularity, and emissions from the different fluorescent dyes. This information is analyzed by computer (CPU). By examining many cells in this way, the number of cells with a specific set of characteristics can be counted and levels of expression of various molecules on these cells can be measured. The bottom part of the figure shows how these data can be represented, using the expression of two surface immunoglobulins, IgM and IgD, on a sample of B cells from a mouse spleen. The two immunoglobulins have been labeled with different-colored dyes. When the expression of just one type of molecule is to be analyzed (IgM or IgD), the data are usually displayed as a histogram, as in the left-hand panels. Histograms display the distribution of cells expressing a single measured parameter (such as size, granularity, fluorescence color). When two or more parameters are measured for each cell (IgM and IgD), various types of two-color plot can be used to display the data, as shown in the right-hand panel. All four plots represent the same data. The horizontal axis represents the intensity of IgM fluorescence, and the vertical axis the intensity of IgD fluorescence. Two-color plots provide more information than histograms; they allow recognition, for example, of cells that are 'bright' for both colors, 'dull' for one and bright for the other, dull for both, negative for both, and so on. For example, the cluster of dots in the extreme lower left portions of the plots represents cells that do not express either immunoglobulin; these are mostly T cells. The standard dot plot (upper left) places a single dot for each cell whose fluorescence is measured. It is good for picking up cells that lie outside the main groups but tends to saturate in areas containing a large number of cells of the same type. A second method of presenting these data is the color dot plot (lower left), which uses color density to indicate high-density areas. A contour plot (upper right) draws 5% 'probability' contours, with 5% of the cells lying between each contour providing the best monochrome visualization of regions of high and low density. The lower right plot is a 5% probability contour map that also shows outlying cells as dots.



(normal). However, none of Bill's peripheral blood lymphocytes bound an antibody against the B-cell marker CD19 (normal 12%) (Fig. 1.4).

T-cell proliferation indices in response to phytohemagglutinin, concanavalin A, tetanus toxoid, and diphtheria toxoid were 162, 104, 10, and 8, respectively (all normal). Serum IgG remained low at 155 mg dl<sup>-1</sup>, and serum IgA and IgM were undetectable.

Bill was started on a preparation of gamma globulin rendered suitable for intravenous administration. He was given a dose of gamma globulin intravenously to maintain his IgG level at 600 mg dl<sup>-1</sup>. He improved remarkably. The rales at his lung bases disappeared. Except for occasional bouts of conjunctivitis or sinusitis, which respond well to oral antibiotic treatment, he remains in good health and leads an active life. He became skilled at inserting a needle into a vein on the back of his hand, and he infuses himself with 15 g of gamma globulin every weekend.


## X-linked agammaglobulinemia.

Males such as Bill with a hereditary inability to make antibodies are subject to recurrent infections. However, the infections are due almost exclusively to common extracellular bacterial pathogens—*Haemophilus influenzae*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, and *Staphylococcus aureus*. An examination of scores of histories of boys with this defect has established that they have no problems with intracellular infections, such as those caused by the common viral diseases of childhood. T-cell number and function in males with X-linked agammaglobulinemia are normal, and these individuals therefore have normal cell-mediated responses, which are able to terminate viral infections and infections with intracellular bacteria such as those causing tuberculosis.

The bacteria that are the major cause of infection in X-linked agammaglobulinemia are all so-called pyogenic bacteria. Pyogenic means pus-forming, and pus consists largely of neutrophils. The normal host response to pyogenic infections is the production of antibodies that coat the bacteria and fix complement, thereby enhancing rapid uptake of the bacteria into phagocytic cells such as neutrophils and macrophages, which destroy them. Since antibiotics came into use, it has been possible to treat pyogenic infections successfully. However, when they recur frequently, the excessive release of proteolytic enzymes (for example elastase) from the bacteria and from the host phagocytes causes anatomical damage, particularly to the airways of the lung. The bronchi lose their elasticity and become the site of chronic inflammation (this is called bronchiectasis). If affected males do not receive replacement therapy—gamma globulin—to prevent pyogenic infections, they eventually die of chronic lung disease.

Gamma globulin is prepared from human plasma. Plasma is pooled from approximately 1000 or more blood donors and is fractionated at very cold temperatures (−5°C) by adding progressively increasing amounts of ethanol. This method was developed by Professor Edwin J. Cohn at the Harvard Medical School during the Second World War. The five plasma fractions obtained are still called Cohn Fractions I, II, III, IV, and V. Cohn Fraction I is mainly composed of fibrinogen. Cohn Fraction II is almost pure IgG and is called gamma globulin. Cohn Fraction III contains the beta globulins, including IgA and IgM; Fraction IV, the alpha globulins; and Fraction V, albumin. Cohn Fraction II, or gamma globulin, is commercially available as a 16% solution of IgG. During the processing of the plasma some of the gamma globulin aggregates, and for this reason the 16% solution cannot be given intravenously. Aggregated gamma globulin acts like immune complexes and causes a reaction of shaking chills, fever, and low blood pressure when given intravenously. Gamma globulin can be disaggregated with low pH or insoluble proteolytic enzymes. It can then be safely administered intravenously as a 5% solution. In newer preparations, fractionation is followed by a further purification step using anion-exchange (DEAE) chromatography to get rid of trace contaminants. To decrease the risk of transmitting infection, the current commercially available products have several virus removal and inactivation steps incorporated into the manufacturing process.

The gene defect in X-linked agammaglobulinemia was identified when the gene was mapped to the long arm of the X chromosome at Xq22 and subsequently



**Fig. 1.4** Clinical FACS™ analysis of a normal individual (top panel) and a patient with X-linked agammaglobulinemia (XLA) (bottom panel). Blood lymphocytes from a normal individual bind labeled antibody to both the B-cell marker CD19 and the T-cell marker CD3 (see top panel). However, blood lymphocytes from an individual such as Bill with X-linked agammaglobulinemia show only binding to antibodies against the T-cell marker CD3. This indicates an absence of B cells in these patients.



cloned. The gene, *BTK*, encodes a cytoplasmic protein tyrosine kinase called Bruton's tyrosine kinase (BTK), which is found in pre-B cells, B cells, and neutrophils. BTK is activated at different stages of B-cell development by the engagement of both the pre-B-cell receptor and the B-cell receptor. BTK phosphorylates several downstream molecules that are essential for BCR signaling and that include the B cell linker protein BLNK, phospholipase C- $\gamma$ 2 and protein kinase B, and is required to mediate the survival and further differentiation of the progenitor B cells in which successful rearrangement of their heavy-chain genes has occurred. It is also required for the survival of mature B cells.

## Questions.

**1** Fig. 1.5 shows Bill's family tree. It can be seen that only males are affected and that the females who carry the defect (Bill's mother and maternal grandmother) are normal. This inheritance pattern is characteristic of an X-linked recessive trait. We do not know whether Bill's aunts are carriers of the defect because neither of them has had an affected male child. Now that the *BTK* gene has been mapped, it is possible in principle to detect carriers by testing for the presence of a mutant *BTK* gene. But there is a much simpler test that was already available at the time of Bill's diagnosis, which is still used routinely. Can you suggest how we could have determined whether Bill's aunts were carriers?

**2** Bill was well for the first 10 months of his life. How do you explain this?

**3** Patients with immunodeficiency diseases should never be given live viral vaccines! Several male infants with X-linked agammaglobulinemia have been given live oral polio vaccine and have developed paralytic poliomyelitis. What sequence of events led to the development of polio in these boys?

**4** Bill has a normal number of lymphocytes in his blood (43% of a normal concentration of 5 100 white blood cells per  $\mu$ l). Only by phenotyping these lymphocytes do we realize that they are all T cells (CD3<sup>+</sup>) and that he has no B cells (CD19<sup>+</sup>). What tests were performed to establish that his T cells function normally?

**5** Bill's recurrent infections were due almost exclusively to *Streptococcus* and *Haemophilus* species. These bacteria have a slimy capsule composed primarily of polysaccharide polymers, which protect them from direct attack by phagocytes. Humans make IgG2 antibodies against these polysaccharide polymers. The IgG2 antibodies 'opsonize' the bacteria by fixing complement on their surface, thereby facilitating the rapid uptake of these bacteria by phagocytic cells (Fig. 1.6). What other genetic defect in the immune system might clinically mimic X-linked agammaglobulinemia?

**6** The doctor noted that Bill had no tonsils even though he had never had his tonsils removed surgically. How do you explain this absence of tonsils, an important diagnostic clue in suspecting X-linked agammaglobulinemia?

**7** It was found by trial and error that Bill would stay healthy and have no significant infections if his IgG level were maintained at 600 mg dl<sup>-1</sup> of plasma. He was told to take 10 g of gamma globulin every week to maintain that level. How was the dose calculated?





Fig. 1.5 Bill's family tree.



**Fig. 1.6 Encapsulated bacteria are efficiently engulfed by phagocytes only when they are coated with complement.** Encapsulated bacteria resist ingestion by phagocytes unless they are recognized by antibodies that fix complement. IgG2 antibodies are produced against these bacteria in humans, and lead to the deposition of complement component C3b on the bacterial surface, where it is cleaved by Factor H and Factor I to

produce iC3b, still bound to the bacterial surface. iC3b binds a specific receptor on phagocytes and induces the engulfment and destruction of the iC3b-coated bacterium. Phagocytes also have receptors for C3b, but these are most effective when acting in concert with Fc receptors for IgG1 antibodies, whereas the iC3b receptor is potent enough to act alone, and is the most important receptor for the phagocytosis of pyogenic bacteria.

**B** Females with a disease exactly mimicking X-linked agammaglobulinemia have been found. Explain how this might happen.

This page intentionally left blank  
to match pagination of print book

# CASE 2

## CD40 LIGAND DEFICIENCY

### Failure of immunoglobulin class switching.

After exposure to an antigen, the first antibodies to appear are IgM. Later, antibodies of other classes appear: IgG predominates in the serum and extravascular space, while IgA is produced in the gut and in the respiratory tract, and IgE may also be produced in the mucosal tissues. The different effector functions of these different antibody classes are summarized in Fig. 2.1. The changes in the class of the antibody produced in the course of an immune response reflect the occurrence

Functional activity	IgM	IgD	IgG1	IgG2	IgG3	IgG4	IgA	IgE
Neutralization	+	-	++	++	++	++	++	-
Opsonization	-	-	+++	*	++	+	+	-
Sensitization for killing by NK cells	-	-	++	-	++	-	-	-
Sensitization of mast cells	-	-	+	-	+	-	-	+++
Activation of the complement system	+++	-	++	+	+++	-	+	-

Distribution	IgM	IgD	IgG1	IgG2	IgG3	IgG4	IgA	IgE
Transport across epithelium	+	-	-	-	-	-	+++ (dimer)	-
Transport across placenta	-	-	+++	+	++	+/-	-	-
Diffusion into extravascular sites	+/-	-	+++	+++	+++	+++	++ (monomer)	+
Mean serum level (mg ml <sup>-1</sup> )	1.5	0.04	9	3	1	0.5	2.1	3×10 <sup>-5</sup>

**Fig. 2.1** Each human immunoglobulin isotype has specialized functions and a unique distribution. The major effector functions of each isotype (+++) are shaded in dark red, while lesser functions (++) are shown in dark pink, and very minor functions (+) in pale pink. The distributions are similarly marked, with the actual average levels in serum of adults shown in the bottom row. \*IgG2 can act as an opsonin in the presence of Fc receptors of a particular allotype, found in about 50% of Caucasians.

TOPICS BEARING ON THIS CASE:

Isotype or class switching

Antibody isotypes and classes

CD40 ligand and class switching

Antibody-mediated bacterial killing